Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...
Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...
With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling ...
In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...
IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...
Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results